Published Date: 26 Jan 2024
Researchers recommend that high-risk patients be given consideration for intensification.
Read Full News1.
Dendritic Cell Therapy Offers No Survival Advantage in Pleural Mesothelioma
2.
Let's Talk Breast Density; Cancer, Movies, and Music; Treatment-Induced Aging?
3.
Prostate cancer detection with PET CT and PET MRI is comparable.
4.
Tafasitamab-Based Combination Boosts PFS in Relapsed/Refractory Follicular Lymphoma
5.
Benzene in Cold Med; Male Cancer Death to Rise 93%; Mail-Order Drugs Compromised?
1.
Emerging and Innovative Therapies in Cancer Treatment and Post-Surgical Care
2.
Unveiling the Mystery Behind Castleman Disease – Understanding Its Causes and Symptoms
3.
Essential Oncology Updates: Diagnosis, Treatment Advances, Tools & Education Resources
4.
Navigating the Stages of Thyroid Cancer: A Guide for Patients
5.
Unveiling the Invisible: The Transformative Role of Radiomics in Precision Oncology
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation